This study is looking at two ways to reduce bleeding in patients with coronary artery disease (a condition where blood vessels supplying the heart become narrowed) who have undergone PCI (percutaneous coronary intervention, a procedure to open narrowed arteries). After an initial period of taking aspirin and a potent P2Y12 inhibitor (like prasugrel or ticagrelor), participants will either switch to taking aspirin plus clopidogrel, or they will stop aspirin and continue taking prasugrel or ticagrelor alone. The study aims to see which approach is better at preventing blood clots, measured by thrombus formation after 30 days. You may be able to join if you are 18 or older, have chronic or acute coronary syndrome, and have already had a PCI and been on specific antiplatelet medications for at least 30 or 90 days, depending on your condition. The study plans to enroll 90 participants, but its current recruitment status is unclear.

Study design

This is an interventional study comparing two different drug regimens. It plans to enroll 90 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for thrombus formation, measured at 30 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.